In tableting suites where relative humidity is held below 40% RH and the Fengshi Huoxue Powder veterinary-grade API exhibits bulk density below 0.45 g/mL, direct compression is frequently replaced by dry granulation because the multi-component extract matrix is hygroscopic. Moisture uptake above 5.0% loss on drying by USP <921> Method I produces sticking on 16-station rotary tablet presses at compression forces above 12 kN, and capping appears when granule oversize exceeds 1.25 mm. A dry granulation route begins with screening the API through a 20-mesh sieve to disrupt soft agglomerates, followed by blending in a 200 L double-cone blender with microcrystalline cellulose 102 at 20–40% w/w, dibasic calcium phosphate dihydrate at 10–15% w/w as a brittle diluent, croscarmellose sodium at 3–5% w/w, and colloidal silicon dioxide at 0.5–1.0% w/w for 15 min at 12 rpm. Sodium stearyl fumarate at 0.5–1.5% w/w is added as a boundary lubricant because residual fatty acids in the extract can increase ejection force when stearate-type lubricants are used. The lubricated blend is compacted on a roller compactor at 40–70 bar hydraulic pressure, then milled through a 0.8–1.25 mm screen to produce granules with a 0.35–0.55 g/mL bulk density. Final compression on a rotary press is set to achieve 50–100 N breaking force by USP <1217>, and tablet weight variation is controlled with an acceptance value not exceeding 15 by USP <905>. A 2.5–4.0% hydroxypropyl methylcellulose film-coating weight gain is applied to reduce moisture ingress and mask the characteristic herbal odor. The finished coated tablet is a 250 mg or 500 mg veterinary tablet for oral administration. Process validation requires batch records under 21 CFR 211.188 and content uniformity testing at 10 sampling locations per blend lot.

Because polysaccharide-rich fractions in the extract matrix show measurable pyrogen affinity, injectable processing starts with endotoxin screening of the bulk powder before reconstitution in water for injection. Endotoxin control is achieved at bulk powder acceptance and not by membrane filtration alone, because 0.22 µm filters do not retain endotoxin. Vials are depyrogenated in a dry-heat tunnel at 250 °C for 30 min. The API is dissolved at 5–25 mg/mL in WFI at 20–40 °C under low-shear agitation for 30–60 min; dissolution above 40 °C is avoided because thermolabile polyphenol fractions may form insoluble aggregates. The pH is adjusted to 5.5–6.5 with 0.1 N hydrochloric acid or sodium hydroxide, and the solution is filtered through a 0.45 µm polyethersulfone prefilter followed by a 0.22 µm membrane validated for bacterial retention. Filtration throughput is limited by viscosity from water-soluble polysaccharides; if pre-filtration viscosity exceeds 15 cP, the filter area is increased rather than raising pressure, because high differential pressure can rupture gel layers and release endotoxin. Endotoxin levels are monitored by USP <85>; the acceptance limit is calculated from the maximum intended dose volume and species body weight, not assigned as a fixed product value. For terminal sterilization, a steam autoclave cycle at 121 °C for 15 min is acceptable only where forced degradation studies show assay loss of the marker components below 5.0%; otherwise aseptic filling under ISO 14644-1 Class 5 conditions is used. Published terminal sterilization stability data for this specific polyherbal extract configuration are limited, so forced degradation data are generated for each batch. Formulations containing sulfite antioxidants are avoided for feline species due to documented sensitivity. Particulate matter in the filled solution must meet USP <788> limits for particles ≥10 µm and ≥25 µm, and filling is performed under nitrogen overlay if the product shows oxygen-dependent color shift. Filled vials are 10 mL or 20 mL single-dose units in Type I glass with a bromobutyl stopper.

Hard-shell encapsulation of the API powder requires fill blends with moisture content below 5.0% by USP <921> and Carr index between 25 and 35 for consistent dosator pickup. The direct fill formulation uses 20–40% w/w API, 30–50% w/w microcrystalline cellulose 102, 10–20% w/w lactose monohydrate or mannitol, 2–4% w/w croscarmellose sodium, and 0.5–1.0% w/w sodium stearyl fumarate. Hygroscopicity of the extract necessitates humidity control at 35–55% RH during encapsulation; gelatin shells become brittle when fill moisture is below 4.0%, and HPMC shells soften above 7.0% shell moisture. Automatic capsule machines with dosator nozzles or tamping pins are operated to maintain fill weight variation within ±5% for a 300–500 mg fill weight. In-process sampling at 15-minute intervals checks fill weight and closure length. Disintegration testing by USP <701> requires immediate-release capsules to disintegrate within 30 min in water at 37±2 °C. Dissolution testing by USP <711> is run in 900 mL of 0.1 N hydrochloric acid at 50 rpm using a paddle apparatus; if the herbal extract matrix floats, sinkers are used, and the acceptance criterion is not below 75% release at 45 min. The completed capsule unit is a size #1 or #0 two-piece HPMC capsule packed in 60 mL HDPE bottles with a desiccant canister to hold headspace moisture below 25% RH.

Before oral powders are blended into drinking water or top-dressed onto feed, the API is diluted with a water-soluble carrier at ratios between 1:10 and 1:50 using geometric dilution. The extract powder has higher bulk density than spray-dried lactose monohydrate, so a V-blender at 50–65% fill volume and 15–20 rpm for 15–20 min is used; overmixing beyond 30 min can generate fines and promote segregation. Carrier particle size is maintained between 75 µm and 150 µm, and the API is pre-sieved through a 20-mesh screen to remove hard agglomerates. Blend uniformity is monitored at 10 sampling points by HPLC or NIR; each sample must fall within 90–110% of the theoretical active content and the relative standard deviation must not exceed 5.0% under 21 CFR 211.110. Final powder loss on drying is held below 5.0%, and packaging is performed at 35% RH or lower in heat-sealed foil-lined pouches. The packed oral powder is a 100 g or 500 g unit for reconstitution in drinking water or feed. Because the polysaccharide-containing extract may not fully dissolve in hard water, field use instructions recommend reconstitution in 20–25 °C water with continuous agitation for 10 min; published solubility data for this specific extract configuration in hard water are limited, so each batch is tested in 250 mL of 500 ppm calcium carbonate equivalent water as a worst-case screen.

Why Fluid-Bed Granulation Reduces Dusting and Improves Dose Uniformity Over Simple Powder Blends

Wet granulation of the extract powder in a fluid-bed dryer is used when dusting from dry blending creates occupational exposure or when dose uniformity in sachet packaging fails USP <905>. A binder solution of 2.5–5.0% w/w povidone K30 in purified water or a 50:50 ethanol-water mixture is sprayed through a two-fluid nozzle at 0.5–2.0 L per kg of dry charge with an inlet air temperature of 55–70 °C and product temperature of 30–38 °C. The exhaust humidity is maintained below 60% RH to prevent defluidization and particle agglomeration on the filter bags. Drying continues until granule moisture content is below 3.0% by USP <921>. The dried granules are sieved through a 0.8 mm screen to remove oversize and through a 0.25 mm screen to remove fines; the accepted fraction has a bulk density of 0.45–0.55 g/mL and a Hausner ratio below 1.25. The final sachet contains 500 mg or 1 g of granules for oral administration. Particle size distribution is checked by USP <786>, and related substances are monitored by HPLC with a photodiode array detector. If ethanol is used in the binder, residual solvent testing by USP <467> is required with a limit of 5,000 ppm for ethanol unless justified by the regulatory file.

Medicated Feed Premix Carrier Loading and Segregation Floor

Premix manufacture for medicated feed requires the extract powder to be loaded onto a solid carrier such as rice hulls, corncob meal, wheat middlings, or calcium carbonate at 1–5% w/w active concentration. A horizontal ribbon mixer is charged first with the carrier, then with 0.25–0.5% w/w vegetable oil to improve particle adhesion and reduce dust. The API is added through a 20-mesh screen to prevent lumping. Mixing proceeds for 10–15 min after all ingredients are charged at 30–60 rpm; mix uniformity is sampled at 10 locations with an acceptance range of 90–110% of label claim and an RSD not exceeding 10%. Carrier particle size is kept within 150–1,000 µm to minimize segregation caused by density differences between the botanical extract and the carrier. The premix is diluted again at the feed mill by adding 0.1–1.0 kg of premix per metric ton of finished feed, depending on the prescribed veterinary inclusion rate. Medicated feed manufacturing must follow 21 CFR Part 225 in the United States or Regulation (EU) 2019/4 in the European Union, including flush sequences for mixers and batch documentation. The packed premix is a 25 kg multi-wall paper bag with an inner polyethylene liner; moisture content is kept below 5.0% to prevent mold growth in storage.

When Polyherbal Oral Solutions Require Co-Solvent and Preservative Co-Loading at High Water Activity

Oral solution production uses purified water complying with USP <1231> at 20–25 °C. The extract powder is dispersed at 10–50 mg/mL, and co-solvents such as propylene glycol or glycerin at 5–15% v/v are added when clarity is not achieved after 30 min of overhead mixing at 500–1,000 rpm. The pH is adjusted to 4.5–6.5 with citrate or phosphate buffer to stabilize phenolic fractions and reduce hydrolysis. After pH adjustment, the batch is held at 2–8 °C for 12 h to screen for precipitation, and the supernatant is filtered through a 10 µm polypropylene filter. For multi-dose containers, sodium benzoate at 0.1% w/v and potassium sorbate at 0.1% w/v are added; antimicrobial effectiveness must meet USP <51> category requirements for oral products. The filled oral solution is packed in amber HDPE bottles of 100 mL, 250 mL, or 1 L to reduce light-induced oxidation. Storage is controlled at 15–30 °C, and in-use stability testing is performed when the product is marketed for multi-day drinking water administration in livestock.